The deal marks Lilly’s first in the M&A arena in 2026 as the company diversifies its pipeline beyond obesity drugs.

Arrowhead’s RNA drugs could aid with “high-quality” weight loss, according to one analyst. Elsewhere, the PD-1/VEGF field got ...

Eli Lilly is in advanced talks to acquire Ventyx Biosciences, which is developing pills for autoimmune conditions, for more ...

Nimbus will apply its computational chemistry and structure-based drug design to a discovery programme in obesity treatment.

In today’s ACT Brief, we examine why representative enrollment remains a barrier in US cancer trials, review Johnson & ...

Biopharma industry zeal for obesity therapeutics does not appear to be dying down any time soon, with Eli Lilly and Co. entering a $1.3 billion deal with Nimbus Therapeutics LLC for a new small ...

Nimbus will ⁠use its ⁠AI to help identify drug candidates, while Lilly will contribute its metabolic-disease expertise to ...

Eli Lilly will partner with Nimbus Therapeutics to develop an oral treatment for obesity and other metabolic diseases, through a multi-year research collaboration and exclusive worldwide license ...

Eli Lilly and Nimbus Therapeutics have entered into a multi-year collaboration and exclusive licensing agreement to develop an oral treatment for obesity and other metabolic diseases. Nimbus, an ...

Privately-held Boston, USA-based Nimbus Therapeutics today announced it has entered into a multi-year research collaboration ...

Eli Lilly and Nimbus Therapeutics have entered into a multi-year collaboration and exclusive licensing agreement to develop an oral treatment for obesity and other metabolic diseases.

Eli Lilly (LLY) stock is in focus as Nimbus Therapeutics expands its research deal to develop an oral obesity drug in a deal ...